Phase 4 Schizophrenia Trial, Recruiting NCT06174116 Sponsor: University of Massachusetts, Worcester Condition: Schizophrenia
Back to Schizophrenia

Phase 4 Schizophrenia Trial, Recruiting

NCT06174116
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with schizophrenia or schizoaffective disorder, confirmed using a standard diagnostic interview
  • People who have been taking clozapine for at least 6 months
  • People whose antipsychotic medication dose has been stable for at least 1 month
  • People who have a well-established history of consistently taking their outpatient medications as prescribed
  • People of childbearing potential who are willing to use appropriate birth control throughout the study

Who may not be able to join:

  • People whose psychiatric condition is considered unstable by the lead doctor overseeing the trial
  • People whose antipsychotic medication dose is not currently stable
  • People who currently meet the criteria for a substance use disorder (other than caffeine or nicotine use)
  • People with significant or unstable medical conditions, including serious heart, liver, or kidney disease
  • People with a history of a seizure disorder (such as epilepsy)
  • People who are currently pregnant or breastfeeding
  • People who have taken the medication lumateperone in the past 3 months
  • People who have taken any of the following antipsychotic medications in the past 3 months: aripiprazole, brexpiprazole, or cariprazine

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Xiaoduo Fan, MD, UMass Chan Medical School

Phone: 5088563027

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
University of Massachusetts, Worcester
Registry
ClinicalTrials.gov
Start date
2 April 2024
Est. completion
1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Body Mass Index (BMI); Waist Circumference; Body Composition - Fat Mass; Body Composition - Total Body Mass; Body Composition - Fat Percentage; HBA1C; Fasting Insulin; LDL Particle; Small LDL Particle; Large HDL Particle; Large VLDL Particle

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov